[go: up one dir, main page]

GT201400159A - PHARMACEUTICAL COMPOSITION THAT INCLUDES ISOMETAMIDIUM CHLORIDE IN SOLUTION FOR THE TREATMENT OF TRIPANOSOMIASIS IN ANIMALS - Google Patents

PHARMACEUTICAL COMPOSITION THAT INCLUDES ISOMETAMIDIUM CHLORIDE IN SOLUTION FOR THE TREATMENT OF TRIPANOSOMIASIS IN ANIMALS

Info

Publication number
GT201400159A
GT201400159A GT201400159A GT201400159A GT201400159A GT 201400159 A GT201400159 A GT 201400159A GT 201400159 A GT201400159 A GT 201400159A GT 201400159 A GT201400159 A GT 201400159A GT 201400159 A GT201400159 A GT 201400159A
Authority
GT
Guatemala
Prior art keywords
volume
weight
tripanosomiasis
treatment
pharmaceutical composition
Prior art date
Application number
GT201400159A
Other languages
Spanish (es)
Inventor
Gonzalez Cordero Auristela
Ochoa Roviro Alberto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46963763&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201400159(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201400159A publication Critical patent/GT201400159A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Communication Control (AREA)

Abstract

COMPOSICIÓN FARMACÉUTICA, QUE COMPRENDE CLORURO DE ISOMETAMIDIUM A UNA CONCENTRACIÓN ENTRE 1 Y 4% (PESO/VOLUMEN), ISOPROPILIDENOGLICEROL O GLICERINFORMAL A UNA CONCENTRACIÓN ENTRE 40 Y 95% (PESO/VOLUMEN), UN POLIOL A UNA CONCENTRACIÓN ENTRE 0 Y 50% (PESO/VOLUMEN), 15-HIDROXIESTEARATO DE POLIETILENGLICOL A UNA CONCENTRACIÓN ENTRE 0,5 Y 7% (PESO/VOLUMEN), EN SOLUCIÓN JUNTO CON EXCIPIENTES FARMACÉUTICAMENTE ACEPTABLES, PARA EL TRATAMIENTO DE LA TRIPANOSOMIASIS EN ANIMALES. LA COMPOSICIÓN FARMACÉUTICA ES UNA SOLUCIÓN INYECTABLE LISTA PARA USAR Y SE PUEDE ADMINISTRAR POR VÍA INTRAVENOSA, SUBCUTÁNEA O INTRAMUSCULAR EN RUMIANTES, ÉQUIDOS Y CAMÉLIDOS. LA COMPOSICIÓN PUEDE COMPRENDER ADEMÁS AGENTES ANTIPARASITARIOS, COMO LA IVERMECTINA, A UNA CONCENTRACIÓN ENTRE 1 Y 5% (PESO/VOLUMEN) PARA EL TRATAMIENTO DE LA TRIPANOSOMIASIS Y LA ELIMINACIÓN DE PARÁSITOS GASTROINTESTINALES Y PULMONARES EN ANIMALES.PHARMACEUTICAL COMPOSITION, WHICH INCLUDES ISOMETAMIDIUM CHLORIDE AT A CONCENTRATION BETWEEN 1 AND 4% (WEIGHT / VOLUME), ISOPROPILIDENOGLICEROL OR GLICERINFORMAL TO A CONCENTRATION BETWEEN 40 AND 95% (WEIGHT / VOLUME AT 50%) WEIGHT / VOLUME), 15-POLYETHYLENE GLYCOL HYDROXIESTEARATE AT A CONCENTRATION BETWEEN 0.5 AND 7% (WEIGHT / VOLUME), IN SOLUTION TOGETHER WITH PHARMACEUTICALLY ACCEPTABLE EXCIPIENTS, FOR THE TREATMENT OF TRIPANOSOMIASIS IN ANIMALS. THE PHARMACEUTICAL COMPOSITION IS AN INJECTABLE SOLUTION READY TO USE AND CAN BE ADMINISTERED INTRAVENOUSLY, SUBCUTANEOUS OR INTRAMUSCULAR IN RUMINANTS, EQUIDS AND CAMELIDS. THE COMPOSITION MAY ALSO UNDERSTAND ANTIPARASITARY AGENTS, LIKE IVERMECTINE, TO A CONCENTRATION BETWEEN 1 AND 5% (WEIGHT / VOLUME) FOR THE TREATMENT OF TRIPANOSOMIASIS AND THE ELIMINATION OF GASTROINTESTINAL AND PULMONARY PARASITES IN ANIMAL.

GT201400159A 2012-01-24 2014-07-17 PHARMACEUTICAL COMPOSITION THAT INCLUDES ISOMETAMIDIUM CHLORIDE IN SOLUTION FOR THE TREATMENT OF TRIPANOSOMIASIS IN ANIMALS GT201400159A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201230092A ES2416004B1 (en) 2012-01-24 2012-01-24 PHARMACEUTICAL COMPOSITION THAT INCLUDES ISOMETAMIDIUM CHLORIDE IN SOLUTION FOR THE TREATMENT OF TRIPANOSOMIASIS IN ANIMALS.

Publications (1)

Publication Number Publication Date
GT201400159A true GT201400159A (en) 2015-11-19

Family

ID=46963763

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201400159A GT201400159A (en) 2012-01-24 2014-07-17 PHARMACEUTICAL COMPOSITION THAT INCLUDES ISOMETAMIDIUM CHLORIDE IN SOLUTION FOR THE TREATMENT OF TRIPANOSOMIASIS IN ANIMALS

Country Status (16)

Country Link
AP (1) AP2014007798A0 (en)
AR (1) AR089037A1 (en)
BR (1) BR112014016926A8 (en)
CL (1) CL2014001780A1 (en)
CO (1) CO6990714A2 (en)
CR (1) CR20140278A (en)
DO (1) DOP2014000161A (en)
EC (1) ECSP14010152A (en)
ES (1) ES2416004B1 (en)
GT (1) GT201400159A (en)
MA (1) MA35868B1 (en)
MX (1) MX2014008172A (en)
NI (1) NI201400075A (en)
PE (1) PE20141472A1 (en)
UY (1) UY34479A (en)
WO (1) WO2013110830A1 (en)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2024008B (en) * 1978-06-28 1983-02-16 Merck & Co Inc Compositions for treating trypanosomiasis infections
GB8805286D0 (en) * 1988-03-05 1988-04-07 Schering Agrochemicals Ltd Trypanocides
US5496830A (en) * 1994-09-14 1996-03-05 Johns Hopkins University Inhibition of hemoflagellates by camptothecin compounds
DE19854143A1 (en) * 1998-11-24 2000-05-25 Chambord Ltd Antiprotozoal composition useful for treating e.g. piroplasmosis, malaria and sleeping sickness comprises pentamidine and an additional biocide
FR2819188B1 (en) * 2001-01-08 2003-03-14 Virbac Sa WATER-SOLUBLE PULVERULENT OR GRANULATED COMPOSITIONS BASED ON PHENANTHRIDINES AND USES THEREOF
AR060926A1 (en) * 2007-05-14 2008-07-23 Ciriaco Quiroga PROPOFOL TRANSPARENT ANESTHETIC SOLUTION, WITH LOW VENOUS IRRITATION.
KR20080102010A (en) * 2007-05-17 2008-11-24 대원제약주식회사 Injectable compositions comprising propofol and methods for preparing the same
DE102008007381A1 (en) * 2008-02-01 2009-08-13 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Amidines and guanidines and their derivatives for the treatment of diseases
WO2011042565A2 (en) * 2009-10-09 2011-04-14 Instituut Voor Tropische Geneeskunde Antiprotozoal activity

Also Published As

Publication number Publication date
CR20140278A (en) 2014-12-02
DOP2014000161A (en) 2014-08-15
ECSP14010152A (en) 2015-08-31
BR112014016926A8 (en) 2017-07-04
BR112014016926A2 (en) 2017-06-13
MX2014008172A (en) 2014-10-06
PE20141472A1 (en) 2014-11-05
MA35868B1 (en) 2014-12-01
ES2416004A1 (en) 2013-07-29
AP2014007798A0 (en) 2014-07-31
CL2014001780A1 (en) 2014-10-24
ES2416004B1 (en) 2014-01-28
UY34479A (en) 2013-07-31
WO2013110830A1 (en) 2013-08-01
NI201400075A (en) 2015-04-13
CO6990714A2 (en) 2014-07-10
AR089037A1 (en) 2014-07-23

Similar Documents

Publication Publication Date Title
GT201700056A (en) USE OF LONG-ACTING GLP-1 / GLUCAGON RECEPTOR DUAL AGONIST FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE.
MX2017010304A (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE MELOXICAM.
MX2013007189A (en) APPROPRIATE METHODS AND COMPOSITIONS FOR HANDLING GLUCOSE IN BLOOD IN ANIMALS.
MX379297B (en) TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE.
CR20140086A (en) COMBINATION TREATMENTS FOR HEPATITIS C
CR20170314A (en) FORMULATION OF GLARGINE / LIXISENATIDA INSULIN FIXED RELATIONSHIP
DOP2017000156A (en) GLUCAGON DERIVATIVES WITH IMPROVED STABILITY
CL2017000664A1 (en) Injectable microparticles for hyper-localized release of therapeutic agents
AR096892A1 (en) A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA
CL2017001843A1 (en) Lixisenatide and / or a pharmaceutically acceptable salt thereof for the treatment of pediatric patients with type 2 diabetes mellitus.
MX394213B (en) SEDATION METHODS AND PARENTERAL FORMULATION FOR USE DURING CRITICAL CARE TREATMENT.
MX2020007760A (en) Compositions and methods of enhancing 5-hydroxytryptophan bioavailability.
AR102778A1 (en) PHARMACEUTICAL COMPOSITION, ITS PREPARATION AND ITS USES
MX389554B (en) STABLE VETERINARY ANTHELMINTIC FORMULATIONS.
ECSP10010567A (en) Use of dronedarone to prepare a medication for the treatment of patients with arrhythmia and who have an increase in creatinine level due to the administration of dronedarone
GT201400159A (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES ISOMETAMIDIUM CHLORIDE IN SOLUTION FOR THE TREATMENT OF TRIPANOSOMIASIS IN ANIMALS
CL2014003326A1 (en) Injectable antioxidant formulation for intravenous use of sodium ascorbate - in high doses, and n-acetylcysteine as oxidizing agents, and deferoxamine as iron chelating agents, plus pharmaceutical excipients; method for administration and use in preventing repertfusion damage in patients with acute myocardial infection, undergoing primary cardiac angioplasty; and kit that contains it.
MX2017007856A (en) Oral care composition.
EA201690070A1 (en) APPLICATION OF ARGININE AND / OR CITRUMININ FOR THE TREATMENT AND / OR PREVENTION OF OSTEOARTHROSIS
CL2019001462A1 (en) Improved composition of lansoprazole and simethicone and process to prepare it.
UY32985A (en) USE OF CELIVARONA TO PREPARE A MEDICINAL PRODUCT FOR THE TREATMENT OF PATIENTS WITH ARRITMIA AND THAT HAVE AN INCREASE OF THE CREATININE LEVEL DUE TO THE ADMINISTRATION OF CELIVARONA
AR102978A1 (en) FORMULATION OF FIXED INSULIN GLARGINE / LIXISENATIDA
IN2013MU02585A (en)
TR201619983A2 (en) PHARMACEUTICAL FORMULATIONS OF DICLOFENAC AND ELETRIPTAN
IN2013MU02587A (en)